Literature DB >> 24385593

Predialysis systolic BP variability and outcomes in hemodialysis patients.

Tariq Shafi1, Stephen M Sozio, Karen J Bandeen-Roche, Patti L Ephraim, Jason R Luly, Wendy L St Peter, Aidan McDermott, Julia J Scialla, Deidra C Crews, Navdeep Tangri, Dana C Miskulin, Wieneke M Michels, Bernard G Jaar, Charles A Herzog, Philip G Zager, Klemens B Meyer, Albert W Wu, L Ebony Boulware.   

Abstract

BP variability (BPV) is an important predictor of outcomes in the general population, but its association with clinical outcomes in hemodialysis patients is not clear. We identified 11,291 patients starting dialysis in 2003-2008 and followed them through December 31, 2008 (median=22 months). Predialysis systolic BPV was assessed over monthly intervals. Outcomes included factors associated with BPV, mortality (all-cause and cardiovascular), and first cardiovascular event (cardiovascular death or hospitalization). Patients' mean age was 62 years, 55% of patients were men, and 58% of patients were white. Modifiable factors associated with higher BPV included obesity, higher calcium-phosphate product levels, and lower hemoglobin concentration; factors associated with lower BPV included greater fluid removal, achievement of prescribed dry weight during dialysis, higher hemoglobin concentration, and antihypertensive regimens without β-blockers or renin-angiotensin system blocking agents. In total, 3200 deaths occurred, including 1592 cardiovascular deaths. After adjustment for demographics, comorbidities, and clinical factors, higher predialysis BPV was associated with increased risk of all-cause mortality (hazard ratio [HR], 1.18; 95% confidence interval [95% CI] per 1 SD increase in BPV, 1.13 to 1.22), cardiovascular mortality (HR, 1.18; 95% CI, 1.12 to 1.24), and first cardiovascular event (HR, 1.11; 95% CI, 1.07 to 1.15). Results were similar when BPV was categorized in tertiles and patients were stratified by baseline systolic BP. In summary, predialysis systolic BPV is an important, potentially modifiable risk factor for death and cardiovascular outcomes in incident hemodialysis patients. Studies of BP management in dialysis patients should focus on both absolute BP and BPV.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24385593      PMCID: PMC3968504          DOI: 10.1681/ASN.2013060667

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

1.  Intradialytic hypertension and the association with interdialytic ambulatory blood pressure.

Authors:  Peter N Van Buren; Catherine Kim; Robert Toto; Jula K Inrig
Journal:  Clin J Am Soc Nephrol       Date:  2011-07       Impact factor: 8.237

Review 2.  Visit-to-visit blood pressure variability and risk for progression of cardiovascular and renal diseases.

Authors:  Patrick Rossignol; Michèle Kessler; Faiez Zannad
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-01       Impact factor: 2.894

3.  Factors associated with intradialytic systolic blood pressure variability.

Authors:  Jennifer E Flythe; Srikanth Kunaparaju; Kumar Dinesh; Kathryn Cape; Harold I Feldman; Steven M Brunelli
Journal:  Am J Kidney Dis       Date:  2011-12-29       Impact factor: 8.860

4.  Probing the mechanisms of intradialytic hypertension: a pilot study targeting endothelial cell dysfunction.

Authors:  Jula K Inrig; Peter Van Buren; Catherine Kim; Wanpen Vongpatanasin; Thomas J Povsic; Robert Toto
Journal:  Clin J Am Soc Nephrol       Date:  2012-06-14       Impact factor: 8.237

5.  Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study.

Authors:  Bruce M Robinson; Lin Tong; Jinyao Zhang; Robert A Wolfe; David A Goodkin; Roger N Greenwood; Peter G Kerr; Hal Morgenstern; Yun Li; Ronald L Pisoni; Rajiv Saran; Francesca Tentori; Tadao Akizawa; Shunichi Fukuhara; Friedrich K Port
Journal:  Kidney Int       Date:  2012-06-20       Impact factor: 10.612

6.  Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease.

Authors:  Markus P Schlaich; Bradley Bart; Dagmara Hering; Anthony Walton; Petra Marusic; Felix Mahfoud; Michael Böhm; Elisabeth A Lambert; Henry Krum; Paul A Sobotka; Roland E Schmieder; Carolina Ika-Sari; Nina Eikelis; Nora Straznicky; Gavin W Lambert; Murray D Esler
Journal:  Int J Cardiol       Date:  2013-02-28       Impact factor: 4.164

7.  Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? Pro position.

Authors:  Rajiv L Agarwal
Journal:  J Am Soc Hypertens       Date:  2012-10-15

8.  Debate from the 2012 ASH Annual Scientific Sessions: should blood pressure be reduced in hemodialysis patients? Con position.

Authors:  Matthew R Weir
Journal:  J Am Soc Hypertens       Date:  2012-11-03

9.  Comparative effectiveness studies to improve clinical outcomes in end stage renal disease: the DEcIDE patient outcomes in end stage renal disease study.

Authors:  L Ebony Boulware; Navdeep Tangri; Patti L Ephraim; Julia J Scialla; Stephen M Sozio; Deidra C Crews; Tariq Shafi; Dana C Miskulin; Jiannong Liu; Wendy St Peter; Bernard G Jaar; Albert W Wu; Neil R Powe; Sankar D Navaneethan; Karen Bandeen-Roche
Journal:  BMC Nephrol       Date:  2012-12-06       Impact factor: 2.388

10.  Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis.

Authors:  T I Chang; J E Flythe; S M Brunelli; P Muntner; T Greene; A K Cheung; G M Chertow
Journal:  J Hum Hypertens       Date:  2013-06-27       Impact factor: 3.012

View more
  17 in total

1.  Blood pressure variability and dialysis: variability may not always be the spice of life.

Authors:  Jennifer E Flythe; Steven M Brunelli
Journal:  J Am Soc Nephrol       Date:  2014-01-02       Impact factor: 10.121

Review 2.  Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis.

Authors:  Keith M Diaz; Rikki M Tanner; Louise Falzon; Emily B Levitan; Kristi Reynolds; Daichi Shimbo; Paul Muntner
Journal:  Hypertension       Date:  2014-07-28       Impact factor: 10.190

Review 3.  Visit-to-Visit Variability of Systolic Blood Pressure and Cardiovascular Disease.

Authors:  Wael F Hussein; Tara I Chang
Journal:  Curr Hypertens Rep       Date:  2015-03       Impact factor: 5.369

4.  Blood pressure variability is independent of systolic pressure in adolescent and young adult patients undergoing hemodialysis.

Authors:  Jingjing Da; Zulong Zhang; Yan Shen; Qian Li; Ying Hu; Yan Zha
Journal:  Pediatr Res       Date:  2018-01-03       Impact factor: 3.756

5.  Intradialytic systolic blood pressure variation can predict long-term mortality in patients on maintenance hemodialysis.

Authors:  Jinbo Yu; Xiaohong Chen; Yaqiong Wang; Zhonghua Liu; Bo Shen; Jie Teng; Jianzhou Zou; Xiaoqiang Ding
Journal:  Int Urol Nephrol       Date:  2021-01-02       Impact factor: 2.370

6.  Variability May Be the "Law of Life," but Blood Pressure Variability May Forebode a Shorter Life.

Authors:  Magdalene M Assimon; Jennifer E Flythe
Journal:  Am J Kidney Dis       Date:  2016-02-18       Impact factor: 8.860

7.  Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease.

Authors:  Tara I Chang; Grace H Tabada; Jingrong Yang; Thida C Tan; Alan S Go
Journal:  J Hypertens       Date:  2016-02       Impact factor: 4.844

Review 8.  Hypertension in hemodialysis patients: an opinion-based update.

Authors:  Tariq Shafi; Sana Waheed; Philip G Zager
Journal:  Semin Dial       Date:  2014-02-05       Impact factor: 3.455

9.  Hemodialysis access type is associated with blood pressure variability and echocardiographic changes in end-stage renal disease patients.

Authors:  Ruoxi Liao; Liya Wang; Jiameng Li; Liping Lin; Si Sun; Yunqin Xiong; Yupei Li; Mei Han; Baihai Su
Journal:  J Nephrol       Date:  2019-01-21       Impact factor: 3.902

Review 10.  Intradialytic Blood Pressure Abnormalities: The Highs, The Lows and All That Lies Between.

Authors:  Magdalene M Assimon; Jennifer E Flythe
Journal:  Am J Nephrol       Date:  2015-11-20       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.